SynthesisJournal of the American Heart Association2018
Ceramide Remodeling and Risk of Cardiovascular Events and Mortality.
Synthesis in Journal of the American Heart Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06424119 (Multi-Center Randomized Study of Clinical and Inflammatory Outcomes in Intensive Cardiac Rehabilitation and Traditional Cardiac Rehabilitation Programs), which is not on this map. Cited by 122 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-Center Randomized Study of Clinical and Inflammatory Outcomes in Intensive Cardiac Rehabilitation and Traditional Cardiac Rehabilitation Programs (CREDIBLE Study)
Who cites it
122 citing papers in PubMed, 1 synthesis or guideline pooled it, 173 citations in OpenAlex.
- Effect of High-Dose Marine Omega-3 Fatty Acids on Atherosclerosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.Nutrients · 2019Pooled it
- Impact of Intended Isocaloric Early versus Late Time-Restricted Eating on Plasma Lipidome in Women with Overweight or Obesity: Secondary Analysis of the ChronoFast Trial.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Trial
- Ceramide and phosphatidylcholine lipids-based risk score predicts major cardiovascular outcomes in patients with heart failure.European journal of clinical investigation · 2025Trial
- Metabolomic Profiles Associated With Blood Pressure Reduction in Response to the DASH and DASH-Sodium Dietary Interventions.Hypertension (Dallas, Tex. : 1979) · 2023Trial
- Alterations in plasma triglycerides and ceramides: links with cardiac function in humans with type 2 diabetes.Journal of lipid research · 2020Trial
- Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease.The Journal of clinical investigation · 2020Trial
- Plasma Ceramides and Sphingomyelins in Relation to Heart Failure Risk.Circulation. Heart failure · 2019Trial
- Article
- Circulating ceramides and sphingomyelins: key biomarkers and targets in cardiovascular prevention.Science China. Life sciences · 2026Review
- Ceramides as Biomarkers and Pharmacological Targets in Heart Failure Pathophysiology.Biomolecules · 2026Review
- Detergents without a drain: the evolutionary logic (and liability) of sphingolipids.Journal of lipid research · 2026Review
- Plasma Ceramides Levels in Severe COVID-19 Disease: Correlations with Survival.Open forum infectious diseases · 2026Article
- Serum Lipidomic Profile Signature of Active Acromegaly and Relationships to Cardiovascular Disease.International journal of molecular sciences · 2026Article
- Exploring Ceramide C16:0 as a Novel Biomarker and Therapeutic Target for Atherosclerosis.Journal of the American Heart Association · 2026Review
- The Role of Ceramides in Metabolic and Cardiovascular Diseases.Journal of cardiovascular development and disease · 2026Review
- Preoperative Cer(d18:1/24:0) Shows Promise as a Candidate Predictor of Plasma Lipid Phenotypes Following Roux-en-Y Gastric Bypass in Women: An Exploratory Analysis of the SURMetaGIT Study.Journal of obesity · 2026Observational
- A Reproducible Ceramide Phenotype of Sepsis Across Aetiologies - A Monocenter Cohort Study.Journal of inflammation research · 2026Article
- Sphingolipid Metabolism: A Pathological Hub Linking Lipid Dysregulation and Chronic Inflammation in Atherosclerotic Cardiovascular Disease.Journal of inflammation research · 2026Review
- Plasma ceramide Cer24:0 and insulin resistance: associations with TyG and TG/HDL-C in a multicenter study of coronary artery disease cohorts.Frontiers in endocrinology · 2026Observational
- Very long-chain saturated fatty acids in plasma lipids: association with cardiometabolic risk influenced by lipid interactions.Cardiovascular diabetology · 2025Article
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundRecent studies suggest that circulating concentrations of specific ceramide species may be associated with coronary risk and mortality. We sought to determine the relations between the most abundant plasma ceramide species of differing acyl chain lengths and the risk of coronary heart disease (CHD) and mortality in community-based samples. METHODS AND
resultsWe developed a liquid chromatography/mass spectrometry assay to quantify plasma C24:0, C22:0, and C16:0 ceramides and ratios of these very-long-chain/long-chain ceramides in 2642 FHS (Framingham Heart Study) participants and in 3134 SHIP (Study of Health in Pomerania) participants. Over a mean follow-up of 6 years in FHS, there were 88 CHD and 90 heart failure (HF) events and 239 deaths. Over a median follow-up time in SHIP of 5.75 years for CHD and HF and 8.24 years for mortality, there were 209 CHD and 146 HF events and 377 deaths. In meta-analysis of the 2 cohorts and adjusting for standard CHD risk factors, C24:0/C16:0 ceramide ratios were inversely associated with incident CHD (hazard ratio per average SD increment, 0.79; 95% confidence interval, 0.71-0.89;
conclusionsThe ratio of C24:0/C16:0 ceramides in blood may be a valuable new biomarker of CHD risk, HF risk, and all-cause mortality in the community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.